Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival

Table 3 Univariate and multivariate predictors of overall survival > 12 mo among patients with immune checkpoint inhibitor colitis (n = 64)

Clinical variables	Univariate predictors			Multivariate predictors
	OR	95%CI	P value	OR	95%CI	P value
Demographics
Age (yr)	0.96	0.92-1.01	0.103	0.93	0.88-0.99	0.023
Male	0.82	0.29-2.32	0.711
Female	1.22	0.43-3.44	0.711
Race
White	0.87	0.23-3.27	0.835
Black	1.00	0.90-1.34	0.996
Asian	0.54	0.07-4.10	0.550
Other	1.07	0.97-1.11	0.912
Type of malignancy
Melanoma	1.26	0.45-3.51	0.654
RCC	0.51	0.12-2.28	0.381
NSCLC	0.53	0.10-2.85	0.456
Sarcoma	2.38	0.25-22.65	0.451
Head and neck SCC	1.05	0.89-1.10	0.865
Other	5.33	0.62-45.68	0.127
Stage IV malignancy	0.60	0.11-3.26	0.554
Presence of high grade IMC	0.91	0.32-2.57	0.855
Type of immune checkpoint inhibitor
Ipilimumab plus nivolumab	0.95	0.31-2.88	0.922
Ipilimumab	0.98	0.25-3.77	0.974
Nivolumab	0.09	0.01-0.83	0.033	0.13	0.01-1.43	0.096
Pembrolizumab	2.74	0.78-9.58	0.114	3.46	0.84-14.19	0.084
Atezolizumab	1.74	0.17-17.73	0.641
Number of ICI infusionsa	0.28	0.04-1.82	0.183
Dose of ICI (mg/kg)	1.88	0.36-9.83	0.457
Prior ICI use	0.46	0.12-1.80	0.265
Medical history
Non-liver, non-upper GI diseaseb	1.67	0.51-5.49	0.397
Personal history of autoimmune diseaseb	0.78	0.26-2.31	0.648
Family history of autoimmune diseaseb	0.93	0.20-4.29	0.922
Prior immune-enhancing therapyb	0.55	0.03-9.23	0.678
Prior interferon-g therapy	1.00	0.99-1.10	0.976
Vitamin D use	2.45	0.80-7.46	0.116	2.77	0.75-10.20	0.124
Smoking (current or prior)	1.66	0.59-5.65	0.334
NSAID use	2.55	0.49-13.16	0.265
Any vaccine	5.33	0.62-45.68	0.127
Flu vaccine	1.46	0.26-8.19	0.668
Pneumonia vaccine	1.00	0.99-1.05	0.995
Other vaccine	1.00	1.00-1.01	0.941
Weight at start of ICI (kg)	1.02	0.98-1.05	0.329
Medications
Steroid at start of ICI	0.98	0.25-3.77	0.974
Steroid duration (d)	1.00	1.00-1.01	0.736
Infliximab use	2.55	0.49-13.16	0.265
Vedolizumab use	1.00	1.00-1.01	0.936

^aNumber of infusions of immune checkpoint inhibitor prior to immune checkpoint inhibitor-mediated colitis diagnosis (cases) or total (controls).

^bSee Supplementary Table 2.

ICI: Immune checkpoint inhibitor; IMC: Immune checkpoint inhibitor-mediated colitis; SD: Standard deviation; RCC: Renal cell carcinoma; NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma; irAE: Immune related adverse event.